首页> 外国专利> ANTISENSE OLIGONUCLEOTIDES AGAINST THYMIDYLATE SYNTHASE

ANTISENSE OLIGONUCLEOTIDES AGAINST THYMIDYLATE SYNTHASE

机译:抗胸苷酸合成酶的反义寡核苷酸

摘要

Antisene oligonucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense oligonucleotides targeted to sequences in the 3' end of TS mRNA, which are both cytostatic on their own when administered to human tumour cell lines, and which also enhance the toxicity of anticancer drugs such as Tomudex. The invention also relates to antisense oligonucleotides targeted to sequences at or near the translation start site at the 5' end of TS mRNA which induce TS gene transcription and enhance cell growth. The invention further relates to a combination product comprising an antisense oligonucleotide in combination with an anticancer agent such as Tomudex (N-(5[N-3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) or the Zeneca development compound ZD 9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino] benzamido-4-(1H-1,2,3,4-tetrazol-5-yl) butyric acid), and to the use of such a combination product in the treatment of cancer.
机译:靶向胸苷酸合酶(TS)mRNA中序列的反烯寡核苷酸。特别地,本发明涉及靶向TS mRNA的3'末端序列的反义寡核苷酸,当施用于人肿瘤细胞系时,它们既具有细胞抑制作用,又增强了抗癌药物如Tomudex的毒性。本发明还涉及靶向于TS mRNA的5'末端的翻译起始位点处或附近的序列的反义寡核苷酸,其诱导TS基因转录并增强细胞生长。本发明进一步涉及包含反义寡核苷酸与抗癌剂例如Tomudex(N-(5 [N-3,4-二氢-2-甲基-4-氧代喹唑啉-6-基甲基)-N-甲基氨基] -2-thenoyl)-L-谷氨酸)或Zeneca显影化合物ZD 9331((S)-2-(2-氟-4- [N-(4-羟基-2,7-二甲基喹唑啉-6- (甲基)-N-(丙-2-炔基)氨基]苯甲酰氨基-4-(1H-1,2,3,4-四唑-5-基)丁酸),并在此类组合物中使用治疗癌症。

著录项

  • 公开/公告号DE69836384T2

    专利类型

  • 公开/公告日2008-02-21

    原文格式PDF

  • 申请/专利权人 SARISSA INC.;ISIS PHARMACEUTICALS INC.;

    申请/专利号DE1998636384T

  • 发明设计人

    申请日1998-09-17

  • 分类号C12N15/11;C07H21/02;A61K31/70;A61K31/505;C07D239/95;C12N9/10;

  • 国家 DE

  • 入库时间 2022-08-21 19:47:31

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号